Procyon Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

Procyon Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-5	Closed	-$1K	–	306
2020 Q2	$1K	Hold	5	–	–	﹤0.01%	970
2020 Q1	$0	Hold	5	–	–	﹤0.01%	1010
2019 Q4	$0	Buy	+5	New	+$378	﹤0.01%	997

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Procyon Advisors's BMRN Position: Q3 2020 in Review

Procyon Advisors sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2020, closing a stake of 5 shares — an estimated $1K sold.

Procyon Advisors first reported a position in BMRN in Q4 2019 and held it in 3 quarters. The position peaked at $1K in Q2 2020. 496 funds tracked by Wall St. Rank hold BMRN as of Q3 2020.

Procyon Advisors reported no remaining BioMarin Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
Procyon Advisors sold 5 BioMarin Pharmaceuticals shares in Q3 2020, an estimated $1K.
Procyon Advisors first reported a position in BioMarin Pharmaceuticals in Q4 2019 and held it in 3 quarters.
Procyon Advisors's BioMarin Pharmaceuticals position peaked at $1K in Q2 2020.
496 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2020.

Based on Procyon Advisors's 13F filing for Q3 2020, filed 22 Oct 2020.